Increased Fatty Acid Synthase Activity in Non-small Cell Lung Cancer Tissue Is a Weaker Predictor of Shorter Patient Survival than Increased Lipoprotein Lipase Activity

Archives of Medical Research

Volumn 41, Issue 6, 2010, Pages 405-409

  Cerne, Darko ^a   Prodan Zitnik, Irena ^a   Sok, Miha ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Enzyme activity; Fatty acid synthase; Gene expression; Lipoprotein lipase; Lung cancer tissue; Survival analysis

Indexed keywords

FATTY ACID SYNTHASE; LIPOPROTEIN LIPASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH; WEIGHT REDUCTION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FATTY ACID SYNTHETASE COMPLEX, TYPE I; FEMALE; GENE EXPRESSION; HUMANS; LIPOPROTEIN LIPASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 78049433812     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.08.007     Document Type: Article

References (25)

1. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-1372.
2. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980.
3. Wang Y., Zhang X.R., Fu J., et al. Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2004, 26:369-372.
4. Van de Sande T., Roskams T., Lerut E., et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 2005, 206:214-219.
5. Alò P.L., Visca P., Marci A., et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996, 77:474-482.
6. Takahiro T., Shinichi K., Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 2003, 9:2204-2212.
7. Bandyopadhyay S., Pai S.K., Watabe M., et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 2005, 24:5389-5395.
8. Rashid A., Pizer E.S., Moga M., et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997, 150:201-208.
9. Visca P., Sebastiani V., Botti C., et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 2004, 24:4169-4173.
10. Sakayama K., Masuno H., Miyazaki T., et al. Existence of lipoprotein lipase in human sarcomas and carcinomas. Jpn J Cancer Res 1994, 85:515-521.
11. Cerne D., Melkic E., Trost Z., et al. Lipoprotein lipase activity and gene expression in lung cancer and in adjacent noncancer lung tissue. Exp Lung Res 2007, 33:217-225.
12. Trost Z., Sok M., Marc J., et al. Increased lipoprotein lipase activity in non-small cell lung cancer tissue predicts shorter patient survival. Arch Med Res 2009, 40:364-368.
13. Nomura K., Noguchi Y., Matsumoto A. Stimulation of decreased lipoprotein lipase activity in the tumour-bearing state by the antihyperlipidemic drug bezafibrate. Surg Today 1996, 26:89-94.
14. Chung C.C., Ohwaki K., Schneeweis J.E., et al. A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production. Assay Drug Dev Technol 2008, 6:361-374.
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
16. Piyathilake C.J., Frost A.R., Manne U., et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000, 31:1068-1073.
17. Orita H., Coulter J., Tully E., et al. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumours. Clin Cancer Res 2008, 14:2458-2464.
18. Wang Y., Zhang X., Tan W., et al. Significance of fatty acid synthase expression in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2002, 24:271-273.
19. Zhang D., Tai L.K., Wong L.L., et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 2005, 4:1686-1696.
20. Nemoto T., Terashima S., Kogure M., et al. Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology 2001, 69:297-303.
21. Pizer E.S., Lax S.F., Kuhajda F.P., et al. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 1998, 83:528-537.
22. Preiss-Landl K., Zimmermann R., Hammerle G., et al. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002, 13:471-481.
23. Mutoh M., Niho N., Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem 2006, 387:381-385.
24. Cerne D. Reply: Increased lipoprotein lipase activity in non-small lung cancer tissue predicts shorter patient survival. Arch Med Res 2010, 41:65.
25. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumours 2002, John Wiley & Sons, New York. 6th ed.